Drug Approval | October 18, 2023
Glenmark receives ANDA approval for Apremilast Tablets
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Lupin enters into BTA with Lupin Manufacturing Solutions
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Animations, colors, and shapes help to improve poor situational awareness, which is responsible for 81.5% of anesthesia-related errors
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
Subscribe To Our Newsletter & Stay Updated
